Drugs /

lanreotide

Back to Drugs List

Overview

Generic Name(s):
lanreotide
Trade Name(s):
Somatuline Depot Injection
NCI Definition [1]:
A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I). This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.

Clinical Trials

View Clinical Trials for lanreotide

Lanreotide has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating lanreotide, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open).

SSTR2 Expression, SSTR1 Expression, and SSTR3 Expression are the most frequent biomarker inclusion criteria for lanreotide clinical trials.

Adrenal gland pheochromocytoma, digestive system neuroendocrine neoplasm, and gastric neuroendocrine tumor are the most common diseases being investigated in lanreotide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lanreotide
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Lanreotide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lanreotide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Somatuline Depot Injection, nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-nh2, lanreotide [chemical/ingredient], naphthyl-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2, dermopeptin, lanreotide, ipstyl, bim-23014, d-nal-cys-tyr-trp-lys-val-cys-thr-nh2, nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-nh2, dc-13-116, 3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine amide, lanreotide (product), somatulina, lanreotide (substance), somatuline, l-threoninamide, 3-(1-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide, dc 13-116, angiopeptin, 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide, nal-cyclo(cys-tyr-trp-lys-val-cys)thr-nh2, naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide, angiopeptin, dc13-116, lanreotide, ipstyl, l-threoninamide, 3-(2-naphthalenyl)-d-alanyl-l-cysteinyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl-l-cysteinyl-, cyclic (2-7)-disulfide, bim 23014, dc 13116, 3-(2-naphthyl)-d-ala-cys-tyr-d-trp-lys-val-cys-thr-nh2
Drug Categories [2]:
Somatostatin receptor agonists
NCIT ID [1]:
C1523
SNOMED ID [1]:
F-B1002

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.